NCT03611686进行中（未招募）不适用
Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies
University Hospital, Rouen1 个研究点 分布在 1 个国家目标入组 219 人开始时间: 2018年4月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 219
- 试验地点
- 1
- 主要终点
- Number of alive patient
研究概览
简要总结
Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patient monitored for castration-resistant metastatic prostate
- •Patients starting a first or second line treatment as part of castration resistance
- •Patient not objecting to the study after reading the information letter
- •Patient aged over 18 years
排除标准
- •Patient monitored for non-metastatic prostate cancer
- •Patient monitored for castration-nonresistant prostate cancer
- •Patient not able to understand the information letter
研究组 & 干预措施
patient followed for metastatic prostate adenocarcinoma
patient wil be followed for metastatic prostate adenocarcinoma during 3 years
干预措施: Local chemotherapy (Drug)
结局指标
主要结局
Number of alive patient
时间窗: 3 years
次要结局
- Number of alive patient disease free(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate CancerProstate CancerNCT01558427University Hospital, Ghent62
已完成
不适用
Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.Prostatic Neoplasms, Castration-ResistantNCT04962919Latin American Cooperative Oncology Group584
Unknown
早期 1 期
Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT04225910Xinhua Hospital, Shanghai Jiao Tong University School of Medicine20
已完成
3 期
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerProstate CancerNCT01809691SWOG Cancer Research Network1,313
招募中
不适用
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical TrialsProstate AdenocarcinomaProstate Cancer MetastaticCastration-resistant Prostate CancerProstate CancerNCT06141993Duke University120